Talk track

Key Messages

Detailed Talk Track

I understand that you’ve been using TISSEEL® to manage bleeding during thoracic wedge resections and while that has been working well, as you mentioned there is additional set up time. I’d like to introduce you to a next generation fibrin sealant, VISTASEAL™, which consists of thrombin and fibrinogen and forms a rapid, adherent, and durable clot on targeted tissue regardless of the patient’s coagulation profile.1-4 With significantly fewer steps, VISTASEAL setup is faster than TISSEEL®†5 with pre-filled syringes and no need for additional warming, allowing you to quickly address the nuisance bleeding and move on with your procedure with the added confidence of reducing the risk of a re-bleed.6,7 When comparing the application and performance of VISTASEAL™ to TISSEEL®, in benchtop testing, the following benefits have been observed.
  • 2.3 times greater adhesion strength than TISEEL®*8
  • Twice the burst pressure compared to TISSEEL®*8,9
  • 2.4 times greater spray coverage area with VISTASEAL™ ASA vs TISEEL® Prima with Snap-lock Gasless Tip Applicator¶§10
The flexible tip may assist in reaching challenging anatomy within the thoracic cavity. Would you be willing to evaluate VISTASEAL™ in your next few high-risk patients to experience the results for yourself?

References

*In benchtop testing using porcine pericardium.
†Based on number of set-up steps and thawing time required for VISTASEAL™ Dual Applicator vs competitors.
¶The mean coverage (95% CI) of 25 cm2 for VISTASEAL™ vs 10.3 cm2 for TISSEEL at a dispensing rate of 0.4 ml/s.
§Refers to the TISSEEL Prima w ith Snap-Lock Gasless Tip Applicator.

1. Bjelovic M, Ayguasonosa J, Kim RD, et al. A prospective, randomized, phase III study to evaluate the efficacy and safety of fibrin sealant Grifols as an adjunct to hemostasis as compared to cellulose sheets in hepatic surgery resections. J Gastrointest Surg. 2018. 22:1939–1949.
2. Nenezic D, Ayguasonosa J, Menyhei G, et al. A prospective, single-blind, randomized, phase III study to evaluate the safety and efficacy of Fibrin Sealant Grifols as an adjunct to hemostasis compared with manual compression in vascular surgery. J Vasc Surg. 2019: doi.org_10.1016_j.jvs.2018.12.051.
3. Lakshman S, Aqua K, Stefanovic A, et al. A prospective, single blind, randomized, phase III study to evaluate and efficacy of fibrin sealant Grifols as an adjunct to hemostasis during soft tissue open surgery. J Invest Surg. 2018;DOI:10.1080_08941939.2018.1489917.
4. VISTASEAL™ Fibrin Sealant (Human). Full Prescribing Information. Instituto Grifols, S.A.
5. Thawing time and set-up steps comparison between VISTASEAL, EVICEL, and TISSEEL. Report 100708726-Rev 2. August 28, 2019. Ethicon, Inc.
6. Shander A, Kaplan LJ, Harris MT, et al. Topical hemostatic therapy in surgery: bridging the knowledge and practice gap. J Am Coll Surg. 2014;219(3):570-579
7. Vyas K, Saha S. Comparison of hemostatic agents used in vascular surgery. Expert Opin Biol. Ther. 2013;13(12):1663-1672.
8. Completion report for Instron testing of tissue adhesion strength of Vistaseal, Evicel, and Tisseel. 100652447. September 14, 2018. Ethicon, Inc.
9. Completion Report for Burst Pressure Testing, No. 100683240. December 10, 2018
10. Comparative Spray Coverage Area testing report betw een VISTASEAL and TISSEEL Prima w ith Gasless Tip. 100858617. December 15, 2020. Ethicon, Inc

CONFIDENTIAL. FOR INTERNAL USE ONLY. NOT FOR USE WITH ANY CUSTOMER OR FOR EXTERNAL DISTRIBUTION.

Close

Click for assets
VISTASEAL™ Resources